Johnson & Johnson ordered to pay Pennsylvania man $8 billion over claims he wasn't warned antipsychotic drug could make him grow breasts
- A man has won $8 billion in punitive damages from Johnson & Johnson over claims antipsychotic drugs gave him breasts without warning.
- Nicholas Murray, 26 was given Risperdal between 2003 and 2008 to treat troubled sleeping, a result of autism, court documents show, but developed gynecomastia, a condition where female breast tissue grows in men.
- Attorneys for Murray said Johnson & Johnson "knew that there was a significant risk of gynecomastia in male children" but "failed to warn healthcare providers."
- Johnson & Johnson denies there is a "significant risk" of developing gynecomastia from Risperdal, and said it would appeal the "grossly disproportionate" penalty.
- Visit Business Insider's homepage for more stories.
A man has been awarded $8 billion in damages over claims he wasn't forewarned his antipsychotic medicine from Johnson & Johnson could cause him to develop breastsA jury at the Philadelphia Court of Common Pleas ruled on Tuesday that Nicholas Murray had been misled by the pharmaceutical giant, and that they should pay the huge damages as a result, Reuters reported.
Murray, now 26, was prescribed the drug Risperdal as a minor by pediatricians between 2003 and 2008 because he had trouble sleeping, a result of "autism spectrum disorder," court documents show.The drug is commonly prescribed to treat schizophrenia and bipolar disorder, but is also used as a sleeping medicine.
Murray claimed taking Risperdal, produced by Johnson & Johnson subsidiary Janssen, caused him to developed gynecomastia, a condition where breast tissue usually found in women starts to grow in men.
Attorneys for Murray, however, argued there was evidence Johnson & Johnson "knew that there was a significant risk of gynecomastia in male children and adolescents but failed to warn healthcare providers."The New York Times reported.
The medical multinational said on Tuesday the $8 billion figure was "grossly disproportionate with the initial compensatory award in this case," and that the they are "confident it will be overturned."
Professor Carl Tobias of the University of Richmond School of Law told Reuters the amount will almost certainly be reduced on appeal in the Supreme Court, and that the jury was simply sending a message.Risperdal was approved in 1993 by the US Food and Drug Administration for severe schizophrenia, but was slowly prescribed for less serious conditions over time.
- From Tata to Maruti and Mahindra — these are the electric cars lined up for launch in 2021
- Farmer protests: Fifth round of talks end in deadlock, next round on December 9
- Odisha forms panels to track adverse events in Covid-19 vaccine programme
- Hry minister, who got 1st dose of Covid vaccine, tests positive (Ld)
- Hundred cops in Ahmedabad found COVID-19 positive in special drive